GCG and colorectal cancer: The pooled analysis reported that the risk of colorectal cancer increased dramatically among patients receiving GLP-1 RAs [RR: 2.31 (1.82–2.93) I2 = 36%, p < 0.0001], suggesting a more than two-fold increase in risk, while the incidence of colorectal cancer was not significantly associated with GLP-1 RAs compared to other drugs [OR: 1.73 (0.21–14.18), p = 0.61, I2 = 100%].